
## Almudena GonzÃ;lez-DomÃ-nguez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4075671/publications.pdf Version: 2024-02-01



Almudena

#	Article	IF	CITATIONS
1	Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. Gynecologic Oncology, 2022, 164, 406-414.	0.6	4
2	Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain. Advances in Therapy, 2021, 38, 4057-4069.	1.3	3
3	Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain. Vaccine, 2021, , .	1.7	2
4	Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. Health and Quality of Life Outcomes, 2020, 18, 329.	1.0	30
5	Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. Journal of Medical Economics, 2020, 23, 1418-1424.	1.0	9
6	The social return on investment of a new approach to heart failure in the Spanish National Health System. ESC Heart Failure, 2020, 7, 131-138.	1.4	10
7	Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study. Global & Regional Health Technology Assessment, 2020, 7, 50-56.	0.2	7
8	The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. European Journal of Health Economics, 2019, 20, 135-147.	1.4	15
9	Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clinical and Translational Oncology, 2019, 21, 1076-1084.	1.2	9
10	Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. BMC Health Services Research, 2014, 14, 46.	0.9	10
11	Economic valuation of informal care in cerebrovascular accident survivors in Spain. BMC Health Services Research, 2013, 13, 508.	0.9	13
12	Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain. Global & Regional Health Technology Assessment, 0, 8, 8-13.	0.2	3
13	Costs of the management of hemophilia A with inhibitors in Spain. Global & Regional Health Technology Assessment, 0, 8, 35-42.	0.2	1